Enacts the "synthetic kratom kills act" to prohibit harmful synthetic and adulterated kratom products; provides that no person, manufacturer, retailer, or other entity shall manufacture, distribute, sell, or offer for sale: synthesized kratom material; any adulterated kratom product; a kratom product that is combustible or intended to be used for vaporization, aerosolization, or injection; a kratom product that is incorporated into, or marketed or labeled as, a conventional food or beverage product; a kratom product that contains flavoring agents or additives specifically designed or marketed to appeal to individuals under twenty-one years of age; a kratom product not contained in child-resistant packaging; a kratom product that mimics a candy product or is manufactured, packaged, or advertised in a way that can be reasonably considered to appeal to individuals under twenty-one years of age; any kratom product to an individual under twenty-one years of age; and any kratom product in which the concentration of 7-hydroxymitragynine exceeds two percent of the concentration of total alkaloids; requires testing and clear labeling.
S10514, titled the “synthetic kratom kills act,” would create a new section of the Public Health Law regulating kratom products in New York. The bill distinguishes between natural kratom leaf products and synthetic, semi-synthetic, or adulterated kratom products, and it would prohibit the manufacture, distribution, sale, or offer for sale of synthesized kratom material, adulterated kratom products, products intended for vaping, aerosolization, injection, or use as conventional food or beverage items, and products designed to appeal to people under 21. It also bars sales of kratom products with 7-hydroxymitragynine above 2% of total alkaloids and prohibits vending-machine sales.
The bill would require all kratom products sold in the state to undergo third-party laboratory testing before each batch or lot is sold or distributed. Testing would have to screen for heavy metals, microbial contamination, pesticide residues, fentanyl and other controlled substances, and synthesized kratom material, while also quantifying total alkaloids, mitragynine, and 7-hydroxymitragynine. Products would need clear labels listing ingredients, potency information, serving guidance, warnings about pregnancy, child safety, age restrictions, and medication interactions, with QR-code or web-link labeling allowed if space is limited.
In terms of state-law impact, the bill would add a detailed regulatory framework to the Public Health Law and give the Department of Health, county and municipal health departments, and law enforcement inspection and enforcement authority. Violations would be handled through civil penalties, product confiscation, license suspensions, and possible permanent revocation for repeated or egregious violations, rather than criminal penalties. The bill also requires manufacturers, distributors, and retailers to keep certificates of analysis and incident reports, authorizes the department to update testing standards by rule, and allows local governments to adopt stricter kratom restrictions.
The general sentiment reflected in the bill text is strongly public-health oriented and permissive toward regulated natural kratom while hostile to synthetic or adulterated products. The findings emphasize consumer safety, youth protection, and harm reduction, while also noting possible benefits of natural kratom for pain relief, mood support, and PTSD-related use. No committee transcript or vote history was provided, so there is no recorded legislative debate or vote-based sentiment to assess beyond the bill’s stated intent.
The main points of contention likely center on how broadly the bill defines synthetic or adulterated kratom, the 2% 7-hydroxymitragynine threshold, and the restrictions on flavored, candy-like, or food/beverage-style products. Potential stakeholders include kratom consumers, veterans and other users who rely on natural kratom, manufacturers and retailers facing testing and labeling costs, public health regulators, and local governments that may want stricter rules. The bill’s compliance timeline and civil-enforcement structure suggest an attempt to balance access with tighter safety controls.
The bill would amend the Public Health Law by creating a new kratom-specific regulatory regime that bans synthetic and adulterated kratom products while allowing natural kratom leaf products subject to testing, labeling, age, packaging, and sales restrictions. It would impose new compliance duties on manufacturers, distributors, and retailers, authorize state and local enforcement, and establish civil penalties, license suspensions, and recordkeeping requirements. It would also preserve local authority to enact stricter kratom rules and give the Department of Health rulemaking power to update standards.
The bill’s stated approach is generally supportive of regulated natural kratom and strongly opposed to synthetic or adulterated products. Its findings frame the measure as a consumer-protection and harm-reduction bill, emphasizing overdose prevention, youth access limits, and product transparency. Because no committee discussion or vote record was provided, there is no external evidence of legislative support or opposition beyond the bill’s text.
Likely areas of contention include the scope of the ban on “synthesized kratom material,” the 2% cap on 7-hydroxymitragynine relative to total alkaloids, and restrictions on flavored, candy-like, or beverage-style products that may affect product marketing and consumer access. Industry stakeholders may object to testing costs, labeling burdens, and license penalties, while public health advocates may support the restrictions as necessary to prevent adulteration, youth appeal, and overdose risk. Consumers who use kratom for pain, mood, or PTSD-related reasons may favor the bill’s protection of natural leaf products but could be concerned about reduced product availability or higher prices.